Key Takeaways
- ARK Invest limited its buying activity to just three companies last week: Figma, Arcturus Therapeutics, and 10x Genomics
- The fund purchased 337,381 Figma shares worth more than $8.1 million on Friday, March 20
- Circle Internet Group saw significant selling, with ARK offloading 45,998 shares valued at nearly $5.9 million through ARKK and ARKW
- Despite achieving 40% revenue growth last quarter, Figma shares remain 83% below their 2025 peak
- Additional sales included positions in Teradyne, Bullish, Guardant Health, and Butterfly Network
Cathie Wood’s ARK Invest demonstrated unusual restraint during the past week, executing purchases in only three stocks as equity markets experienced their fourth consecutive weekly decline. All three primary market indices recorded losses throughout this period.
The limited purchasing activity represents a departure from Wood’s typical approach of deploying capital more aggressively during market corrections, catching the attention of market observers.
ARK’s buying activity centered exclusively on Figma, Arcturus Therapeutics, and 10x Genomics. Simultaneously, the investment firm liquidated positions across multiple holdings, most notably Circle Internet Group, a cryptocurrency-adjacent company.
Figma operates as a collaborative design platform delivered through the cloud, serving professionals who create websites, applications, and other digital experiences. On March 20, ARK accumulated 337,381 shares through its ARKK and ARKW exchange-traded funds in a transaction valued at $8,171,367.
Shares have plummeted 83% from their summer 2024 highs, following a dramatic surge that saw the stock more than quadruple from its $33 initial public offering price. Yet the company’s fundamentals remain robust, with its latest quarterly results showing revenue expansion of 40%, accelerating from 38% in the prior period.
The company’s net dollar-retention metric reached 136%, indicating that existing clients increased their platform spending by 36% year-over-year. This marks the strongest performance on this indicator in 24 months.
Wall Street forecasters project revenue growth will moderate to 30% for the current year and 20% in the following year. The stock’s decline reflects concerns over Figma’s lack of consistent profitability.
Cryptocurrency-Linked Holdings Face Reduction
In the digital asset space, ARK divested 45,998 shares of Circle Internet Group distributed between ARKK and ARKW funds, generating proceeds of $5,902,923. The firm had been systematically trimming this position throughout the week.
Circle Internet operates as a major player in the cryptocurrency infrastructure sector, particularly recognized for its involvement with the USD Coin stablecoin.
Additional sales included 19,206 Teradyne shares for $5,807,894, alongside 103,379 Bullish shares totaling $4,093,808 and 9,621 Guardant Health shares worth $857,038. ARK also liquidated 182,353 Butterfly Network shares for $723,941.
Biotechnology Investments: Arcturus and 10x Genomics
Arcturus Therapeutics specializes in messenger RNA-based therapeutics targeting uncommon respiratory and liver conditions. ARK accumulated Arcturus shares on three separate trading sessions during the week, with the most recent transaction occurring Friday when 22,773 shares were purchased for $153,034 through the ARKG ETF.
Arcturus has experienced three consecutive years of revenue contraction, with projections indicating further declines extending into 2026. The company recently announced an extension of its cash reserves sufficient to operate through at least the second quarter of 2028.
10x Genomics develops advanced instrumentation for life sciences research, highlighted by its Chromium system designed for single-cell genomic evaluation. Last week, ARK acquired 192,658 shares distributed between ARKK and ARKG funds, representing an investment of $3,541,054.
The stock debuted publicly at $38 per share and currently trades near half that valuation. The company has yet to achieve profitability, and management’s 2026 outlook anticipates declining revenues when adjusted for one-time licensing revenue from patent settlements recorded in the previous year.
